Critical Review: Clearside Biomedical (CLSD) & Heat Biologics (HTBX)

Clearside Biomedical (NASDAQ: CLSD) and Heat Biologics (NASDAQ:HTBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Risk & Volatility

Clearside Biomedical has a beta of -8.67, indicating that its stock price is 967% less volatile than the S&P 500. Comparatively, Heat Biologics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Earnings & Valuation

This table compares Clearside Biomedical and Heat Biologics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clearside Biomedical $520,000.00 292.38 -$25.88 million ($2.12) -2.83
Heat Biologics $340,000.00 39.41 -$12.57 million ($3.90) -0.82

Heat Biologics has lower revenue, but higher earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Heat Biologics, indicating that it is currently the more affordable of the two stocks.


This table compares Clearside Biomedical and Heat Biologics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clearside Biomedical -17,684.07% -90.72% -71.95%
Heat Biologics -1,184.92% -149.69% -92.51%

Insider & Institutional Ownership

51.7% of Clearside Biomedical shares are held by institutional investors. Comparatively, 66.9% of Heat Biologics shares are held by institutional investors. 20.9% of Clearside Biomedical shares are held by company insiders. Comparatively, 8.7% of Heat Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Clearside Biomedical and Heat Biologics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearside Biomedical 0 0 5 0 3.00
Heat Biologics 0 0 2 0 3.00

Clearside Biomedical currently has a consensus target price of $20.00, suggesting a potential upside of 233.33%. Heat Biologics has a consensus target price of $22.50, suggesting a potential upside of 605.33%. Given Heat Biologics’ higher possible upside, analysts clearly believe Heat Biologics is more favorable than Clearside Biomedical.


Clearside Biomedical beats Heat Biologics on 7 of the 12 factors compared between the two stocks.

About Clearside Biomedical

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

About Heat Biologics

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with's FREE daily email newsletter.

Leave a Reply